Mehmooda begum medical complex
Welcome,         Profile    Billing    Logout  
 10 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rehman, Syed
KIDCARES10, NCT04944979: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients

Recruiting
3
30
Europe, US, RoW
Kedrion IVIG 10%
Kedrion S.p.A.
Primary Immunodeficiency Disease
04/26
10/26
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Recruiting
3
100
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, placebo
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
11/25
01/32
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
07/26
12/28
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Recruiting
3
1021
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
07/27
08/27
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Active, not recruiting
2
108
Canada, US
CRS3123, Active Comparator
Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
02/24
04/24
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
114
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
01/25
02/25
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
Khan, Hafsa
No trials found

Download Options